Linking Blood Levels of Tuberculosis Drugs to Treatment Results and Side Effects
Studies whether tuberculosis drug blood levels relate to how well treatment works and its safety.
Plain-language title generated from the registry record
Registry title: Collect Data From Patients Receiving Standardized Anti-tuberculosis Therapy, Collect Monitoring Data, and Evaluate Treatment Efficacy and Potential Adverse Reactions.
Key facts
- Where
- Beijing, ChinaSee the site
Where in China
- Beijing chest hospital affiliated to Capital medical university, Beijing Tuberculosis & Thoracic Tumor Research InstituteBeijing, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Beijing Chest Hospital
- Trial code
- NCT07607288
- Record updated
- 26 May 2026
- Original description
The purpose of this clinical trial is to investigate the correlation between anti-tuberculosis drug concentration monitoring and treatment efficacy and safety through analytical studies.The main questions it aims to answer include:Read full original descriptionShow less
Clinical Study on the Correlation Between Plasma Concentrations of Antituberculosis Drugs and Treatment Efficacy/Safety.
The purpose of this clinical trial is to investigate the correlation between anti-tuberculosis drug concentration monitoring and treatment efficacy and safety through analytical studies.The main questions it aims to answer include:
Guidance for individualized dosage adjustment of anti-tuberculosis drugs; Guidance on medication challenges for special populations and patients with comorbidities;Address the dose optimization issue for refractory tuberculosis.
Inclusion: Patients with tuberculosis confirmed by bacteriological or pathological diagnosis; Those who have received standardized anti-tuberculosis treatment regimens; Patients with complete clinical records and completed follow-up for at least one treatment course.
Exclusion: Concurrent chronic liver diseases such as chronic hepatitis B, hepatitis C, or alcoholic liver disease; Concurrent severe underlying cardiac conditions (e.g.,congenital heart disease, cardiomyopathy, severe arrhythmias); Concurrent use of multiple medications that may affect cardiac function; Human immunodeficiency virus (HIV) co-infection; Baseline alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels>2 times the upper limit of normal; Women who are pregnant or breastfeeding.